Drug Repurposing for Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 55509
Special Issue Editor
Interests: ovarian cancer; drug repurposing; ovarian cancer development; immunogenic cell death; ER stress
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
During the last few decades, we have made great advances in understanding cancer at organismal, cellular, and molecular levels. Thanks to these discoveries, disease-free survival and overall survival from cancers has significantly improved. For instance, by finding early biomarkers of disease initiation, we have been able to diagnose patients at much earlier stages of disease. Additionally, accrued knowledge about the genetic defects driving cancer malignancy and tumor microenvironment has permitted the development of targeted therapeutic approaches. Despite all of this progress, however, we have new paths to chart, paths that could reduce disease mortality sooner rather than later. Drug repurposing opens up such an expedient avenue of investigation. Any compound that, upon repurposing, reaches the clinic, will do so in a rapid manner and at reduced costs.
In this Special Issue, we propose encompassing a series of articles dealing with evidence that supports using compounds for cancer therapy that have already been approved worldwide by healthcare systems to treat other diseases or conditions. Many drugs and natural compounds used for particular purposes have shown indirect beneficial effects against cancer initiation, progression, and/or metastasis as single agents or in combination with standard chemo and/or radiotherapy. For example, the treatment of patients with metformin, originally developed for type II diabetes, has reduced the incidence of breast cancer and has led to the study of metformin as an anti-cancer agent.
While we should keep developing new diagnostic tools and better-targeted therapies, we should also explore the potential of thousands of drugs and compounds that have been tested for specific healthcare uses, yet were discarded because of reduced efficacy. After all, what might be less efficacious in one scenario might be the more in another. Through this Special Issue, we will introduce a series of relatively unknown compounds not originally developed for cancer therapy, to the field of cancer therapy, that demonstrate anti-cancer properties in in vitro and in vivo studies.
Prof. Dr. Carlos M. Telleria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- drug repositioning
- drug repurposing
- old drugs for new uses
- new drugs
- natural compounds
- small molecules
- alternative therapies
- new indications
- multi-targeted drugs
- “off-patent” drugs